Millie
your market intelligence analyst
Search Results
222 results
Your search is now limited to «Amgen» expert search.
BioPharma Dive 07/19/2019 11:35
Amgen, Allergan launch first US biosimilars of Roche's Herceptin and Avastin.
More from BioPharma Dive:
PharmaManufacturing 07/19/2019 11:20
Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States.
More from PharmaManufacturing:
ENDPOINTS 07/19/2019 10:48
Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab ...
More from ENDPOINTS:
Amgen News Release 07/18/2019 23:00
About Amgen Biosimilars Amgen is committed to building upon Amgen's experience in the development and manufacturing of innovative human therapeutics to expand Amgen's reach to patients with serious illnesses.
More from Amgen News Release:
FierceMedicalDevices 07/17/2019 07:33
Hayes, the former head of biologics at Amgen, joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type I into clinical testing.
More from FierceMedicalDevices:
FierceBiotech 07/16/2019 14:14
GNS Healthcare's AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene.
More from FierceBiotech:
socalTECH.com 07/15/2019 08:10
Thousand Oaks-based Amgen, along with partners Novartis and the Banner Alzheimer's Institute, said late last week that they are discontinuing a clinical research program, which had focused on Alzheimer's prevention.
More from socalTECH.com:
Benzinga 07/12/2019 10:19
A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: )'s Janssen unit; Merck & Co., Inc. (NYSE: ); and Eli Lilly And Co (NYSE: ) in collaboration with AstraZeneca plc (NYSE: ) all scrapped their respective BACE inhibitor programs in 2018. On Thursday, another pharma partnership threw in the towel. Novartis, Amgen Give Up. Novartis AG (NYSE: ), Amgen, Inc. (NASDAQ: ) and the Banner Alzheimer's Institute announced Thursday after the market close their decision to discontinue the clinical trials of CNP520, a BACE1 inhibitor that was being evaluated for preventing in two pivotal Phase 2/3 studies. The decision follows an assessment of unblinde.
More from Benzinga:
Zacks.com 07/12/2019 10:10
For the most recent quarter, Amgen was expected to post earnings of $3.45 per share, but it reported $3.56 per share instead, representing a surprise of 3.19.
More from Zacks.com:
FiercePharmaManufacturing 07/12/2019 10:05
A German court ruled that Praluent steps on an Amgen patent, hitting partners Sanofi and Regeneron with an injunction.
More from FiercePharmaManufacturing:
Pharmafile 07/12/2019 04:01
Novartis and Amgen halt trials into Alzheimer's drug after patients get worse.
More from Pharmafile:
Novartis, Amgen and Banner Alzheimer's Institute have decided to halt the clinical programme with BACE1 inhibitor CNP520 (umibecestat) for the prevention of Alzheimer's disease.
More from Pharmaceutical Business Review:
Reuters.com 07/11/2019 17:39
Amgen Inc:
More from Reuters.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications